Description
Latin name
AMIGRENIN
Release form
Tablets, film-coated white or white with a grayish-cream tint, round, biconvex in cross section, one or two layers are visible, the inner layer is white or white with a yellowish tint.
packaging 6 pcs – blister packagings (1) – packs of cardboard.
Pharmacological action
Antimigraine drug. A specific selective agonist of serotonin 5HT1B-1D receptors (5-hydroxytryptamine-1-like) located primarily in the smooth muscles of the walls of the blood vessels of the brain.
Stimulation of 5HT1 receptors leads to selective narrowing of blood vessels in the carotid artery system and a decrease in neurogenic inflammation, without significantly affecting cerebral blood flow. In addition, it has been experimentally established that sumatriptan inhibits trigeminal nerve activity.
It is believed that these effects help to reduce the severity of pain in migraines.
Clinical effect is observed 30 minutes after oral administration of the drug.
Indications
– relief of acute migraine attacks with or without aura.
Contraindications
– hemiplegic, basilar and ophthalmoplegic forms of migraine
– IHD (incl. angina pectoris)
– peripheral arterial occlusion disease
– uncontrolled arterial hypertension
– stroke or transient cerebrovascular accident (including history)
– severe liver dysfunction
– concomitant use of drugs containing its ergot or taking MAO inhibitors and the period up to 14 days after they are canceled
– pregnancy
– lactation (breastfeeding)
– age of patients under 18 years and over 65
– increased feel nost to the drug.
Use during pregnancy and lactation
The drug is contraindicated in pregnancy and lactation (breastfeeding).
Composition
1 tab. sumatriptan (as succinate) 0.05 g
Excipients:
MCC
milk sugar
starch potato
sodium carboxymethyl starch
magnesium stearic acid
hydroxypropyl cellulose or hydroxypropyl methyl cellulose
PVP
polyethylene glycol 4000 srdl01 pldrdfp trdldp01 pldrdfp Sumatriptan (as succinate)
0.05 g Excipients:
MCC
milk sugar
potato starch
sodium carboxymethyl
magnesium stearate
hydroxypropylcellulose or hydroxypropylmethyl cellulose PVP
polyethylene glycol 4000
talc titanium dioxide
Dosage and administration
Amigrenin is not intended for prophylactic use.
Adults are prescribed a single dose of 50 mg, in some cases 100 mg. The maximum daily dose is 300 mg.
If the symptoms of migraine do not disappear and do not decrease after taking the first dose of Amigrenin, then the drug should not be prescribed again to stop the ongoing attack.
If symptoms have decreased or disappeared and then resumed, you can take a second dose over the next 24 hours. The interval between doses should be at least 2 hours.
Side effects of
From the cardiovascular system: flushing of the skin and mucous membranes, hypotension, tachycardia, palpitations, angina attack, transient increase in blood pressure, transient ECG changes of the ischemic type, bradycardia in isolated cases – manifestations of Raynaud’s syndrome.
From the side of the central nervous system: dizziness, weakness, drowsiness, fatigue, visual impairment (diplopia, scotoma, decreased visual acuity).
From the digestive system: discomfort in the abdomen, dysphagia, nausea, vomiting rarely – ischemic colitis, increased activity of liver enzymes.
Allergic reactions: rash, itching, erythema, urticaria, anaphylaxis.
Others: tingling, heat, heaviness, pressure or contraction in various parts of the body, myalgia are possible.
overdose
Treatment: In case of overdose, the patient should be observed for 10 hours, carrying out symptomatic therapy as needed.
Storage conditions
List B. The drug should be stored in a dry, dark place.
Expiration
2 years.
Deystvuyuschee substances
sumatriptan
Pharmacy terms
Prescription
Dosage
Dosage Form
tablets
